Active, not recruitingPHASE1, PHASE2NCT01744223
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bellicum Pharmaceuticals
- Principal Investigator
- Bellicum PharmaceuticalsBellicum Pharmaceuticals, Inc.
- Intervention
- BPX-501 dose 1(biological)
- Enrollment
- 36 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2013 – 2032
Study locations (8)
- Emory University Winship Cancer Institute, Atlanta, Georgia, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- University Hospitals of Cleveland, Cleveland, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Baylor Sammons Cancer Center, Dallas, Texas, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01744223 on ClinicalTrials.govOther trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06326008Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical TrialBeijing GoBroad Hospital
- RECRUITINGPHASE2NCT06859424A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationCenter for International Blood and Marrow Transplant Research
- RECRUITINGPHASE2, PHASE3NCT06860269A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic LeukemiaAssistance Publique - Hôpitaux de Paris
- RECRUITINGNCT06895538Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic MalignancyPeking University First Hospital
- RECRUITINGNANCT06960993Mosaic Trial for Stem Cell Transplant RecipientsNorthwestern University
- RECRUITINGPHASE2NCT06816134Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT06608732Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.Institute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGNANCT05968963Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell TransplantationUniversity of Miami
See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement →